Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Unichem Laboratories Ltd

About the Company - Unichem Laboratories Ltd

Unichem Laboratories Ltd. is a Public Limited Listed company incorporated on 22/08/1962 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1962PLC012451 and registration number is 012451. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 942.93 Cr. and Equity Capital is Rs. 14.08 Cr. for the Year ended 31/03/2022.
PharmaceuticalsUnichem Bhavan, Mumbai Maharashtra
NamePosition Held
Dr. Prakash A ModyChairman, Non Ind & Non Exe Director
Mr. Pabitrakumar Kalipada BhattacharyyaManaging Director
Mr. Pranay Premchand GodhaNon Exe.Non Ind.Director
Ms. Priti PuriIndependent Director
Mr. Prafull ShethIndependent Director
Mr. Anand MahajanIndependent Director
Mr. Prafull AnubhaiIndependent Director

Unichem Laboratories Ltd. Share Price Update

Share PriceValue
Previous Day₹516.80

Basic Stock Data of Unichem Laboratories Ltd

Market Cap 3,835 Cr.
Current Price 545
High / Low580/272
Stock P/E
Book Value 342
Dividend Yield0.00 %
ROCE4.58 %
ROE7.05 %
Face Value 2.00

Data Source:

Competitors of Unichem Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Bliss GVS Pharma Ltd 1,306 Cr. 125150/69.214.9 88.80.40 %11.8 %8.30 % 1.00
Wanbury Ltd 523 Cr. 160166/33.021.9 6.800.00 %16.9 %% 10.0
Torrent Pharmaceuticals Ltd 88,045 Cr. 2,6012,700/1,44661.5 1980.85 %19.8 %20.0 % 5.00
Lincoln Pharmaceuticals Ltd 1,292 Cr. 645715/31914.8 2730.24 %21.7 %15.5 % 10.0
Glenmark Pharmaceuticals Ltd 25,511 Cr. 904923/414206 3310.28 %14.2 %5.44 % 1.00
Industry Average127.6 Cr367.263.82179.520.35%16.88%9.85%5.4

Unichem Laboratories Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Operating Profit3019-26-168-1-18-431628938
OPM %9%7%-1%2%-0%18%-0%-6%-14%4%7%2%9%
Other Income16816315148416-289679
Profit before tax233-9-16-1158-21-47-61-472-2284
Tax %-0%114%-27%17%-24%-23%-13%-50%-4%6%132%-12%-0%
Net Profit24-0-11-13-1471-23-71-64-44-1-2484
EPS in Rs3.35-0.06-1.63-1.82-2.0010.15-3.32-10.04-9.08-6.29-0.10-3.4811.93

Unichem Laboratories Ltd Quarterly Chart

Unichem Laboratories Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit118174178101164-41-128-74-499172-4691
OPM %14%16%16%8%12%-6%-16%-6%-4%7%6%-3%5%
Other Income10138320151842,73591915047-065
Profit before tax9414621277137972,548-58-485122-17617
Tax %24%22%20%3%21%-12%0%59%-25%33%-50%-15%
Net Profit71113169751081092,545-24-603433-20215
EPS in Rs7.8912.5218.688.3111.9011.96361.82-3.38-8.554.874.70-28.722.06
Dividend Payout %38%36%43%24%17%25%1%-118%-47%82%85%-14%

Unichem Laboratories Ltd Profit & Loss Yearly Chart

YoY Net Profit Growth
YoY Net Profit Growth (%)59.15%49.56%-55.62%44.00%0.93%2234.86%-100.94%-150.00%156.67%-2.94%-712.12%
Change in YoY Net Profit Growth (%)0.00%-9.60%-105.18%99.62%-43.07%2233.94%-2335.81%-49.06%306.67%-159.61%-709.18%

Unichem Laboratories Ltd Growth

Compounded Sales Growth
10 Years:2%
5 Years:11%
3 Years:7%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
Stock Price CAGR
10 Years:10%
5 Years:23%
3 Years:20%
1 Year:67%
Return on Equity
10 Years:15%
5 Years:-2%
3 Years:-2%
Last Year:-7%

Unichem Laboratories Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital18181818181814141414141414
Other Liabilities280318302264283359359323407436351444372
Total Liabilities9871,0731,1451,1531,2741,5213,1903,1423,1453,1123,3193,1933,070
Fixed Assets4084484194164034915788108708849901,2571,227
Other Assets4514546235746207661,4731,3131,3951,2691,5711,7871,720
Total Assets9871,0731,1451,1531,2741,5213,1903,1423,1453,1123,3193,1933,070

Unichem Laboratories Ltd Reserves and Borrowings Chart

Abbott India Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 124171877811268-112-3282033-260-85
Cash from Investing Activity -102-11836-52-85-1321,648-286-36-66100241
Cash from Financing Activity -14-51-95-51-3359-881-2-62-121191-81
Net Cash Flow8128-25-7-4655-616-78-1543275

Unichem Laboratories Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days767063586016512413512974142160
Inventory Days183132192171184397278278374518527414
Days Payable162145142114131297230182236202161193
Cash Conversion Cycle9757113116113265172231267390508382
Working Capital Days8159958994225200227217194277273
ROCE %14%20%19%9%15%9%128%-2%-2%2%1%-5%

Unichem Laboratories Ltd Financial Efficiency Indicators Chart

Unichem Laboratories Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders33,73434,25833,89235,31333,55732,66629,57330,61829,41826,64221,58420,877

Unichem Laboratories Ltd Shareholding Pattern Chart

No. of Unichem Laboratories Ltd Shareholders

Unichem Laboratories Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
HDFC Small Cap Fund - Regular Plan54731340.83222.15
DSP Healthcare Fund7355911.4829.86
HDFC Pharma and Healthcare Fund1268800.795.15
Motilal Oswal Nifty Microcap 250 Index Fund230060.150.93
Motilal Oswal S&P BSE Healthcare ETF3660.160.01

Unichem Laboratories Ltd ROCE Trend

Unichem Laboratories Ltd EPS Trend

Unichem Laboratories Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)-28.724.704.88-8.55-3.38
Diluted EPS (Rs.)-28.724.704.88-8.55-3.38
Cash EPS (Rs.)-7.1317.8016.912.946.18
Book Value[Excl.RevalReserv]/Share (Rs.)345.89371.90363.16359.54372.23
Book Value[Incl.RevalReserv]/Share (Rs.)345.89371.90363.16359.54372.23
Revenue From Operations / Share (Rs.)190.75180.36175.43156.76167.66
PBDIT / Share (Rs.)-0.9917.0920.075.752.12
PBIT / Share (Rs.)-
PBT / Share (Rs.)-19.573.277.36-6.96-8.52
Net Profit / Share (Rs.)-23.254.854.92-8.66-3.39
NP After MI And SOA / Share (Rs.)-28.724.704.88-8.55-3.38
PBDIT Margin (%)-0.529.4711.433.661.26
PBIT Margin (%)-8.972.294.61-3.73-4.44
PBT Margin (%)-10.261.814.19-4.44-5.08
Net Profit Margin (%)-12.182.682.80-5.52-2.02
NP After MI And SOA Margin (%)-15.052.602.77-5.45-2.01
Return on Networth / Equity (%)-8.301.261.34-2.37-0.90
Return on Capital Employeed (%)-4.711.052.17-1.59-1.98
Return On Assets (%)-6.330.991.09-1.91-0.75
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.340.300.350.290.31
Current Ratio (X)2.492.992.722.984.05
Quick Ratio (X)1.511.901.662.283.38
Inventory Turnover Ratio (X)0.920.871.151.221.62
Dividend Payout Ratio (NP) (%)0.0085.1882.04-56.410.00
Dividend Payout Ratio (CP) (%)0.0022.6623.72158.000.00
Earning Retention Ratio (%)0.0014.8217.96156.410.00
Cash Earning Retention Ratio (%)0.0077.3476.28-58.000.00
Interest Coverage Ratio (X)-0.4019.7027.605.161.98
Interest Coverage Ratio (Post Tax) (X)-8.456.597.77-6.77-2.41
Enterprise Value (Cr.)2147.122049.282195.831015.821368.34
EV / Net Operating Revenue (X)1.601.611.780.921.16
EV / EBITDA (X)-304.9717.0315.5425.0991.72
MarketCap / Net Operating Revenue (X)1.521.441.760.961.16
Retention Ratios (%)0.0014.8117.95156.410.00
Price / BV (X)0.830.700.850.420.52
Price / Net Operating Revenue (X)1.521.441.760.961.16

Unichem Laboratories Ltd Profitability Ratios (%)

Unichem Laboratories Ltd Liquidity Ratios

Unichem Laboratories Ltd Liquidity Ratios (%)

Unichem Laboratories Ltd Interest Coverage Ratios (X)

Unichem Laboratories Ltd Valuation Ratios

Fair Value / Intrinsic Value of Unichem Laboratories Ltd

Fair Value: ₹368.90

The stock is overvalued by 32.31% compared to the current price ₹545

*Investments are subject to market risks

Strength and Weakness of Unichem Laboratories Ltd

  1. The stock has a high average ROCE of 17.33%, which is a positive sign.
  2. The company has higher reserves (1,748.54 cr) compared to borrowings (144.92 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (184.46 cr) and profit (44.08 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of -3.64 and average Dividend Yield of -2.05%.
  2. The stock has a high average Working Capital Days of 169.25, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 225.92, which may not be favorable.

Should I Buy Abbott India Ltd Share Now?

  • Considering various financial indicators, investors might exercise caution regarding investment in Unichem Laboratories Ltd:
    1. Net Profit Margin: -12.18%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -4.71% (Industry Average ROCE: 16.88%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): -8.45
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 1.51
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 13.74)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.12
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Unichem Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE